These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30221605)

  • 1. Clinical and Serological Biomarkers of Treatment's Response in Multiple Sclerosis Patients Treated Continuously with Interferonβ-1b for More than a Decade.
    Bărcuţean LI; Romaniuc A; Maier S; Bajko Z; Moţăţăianu A; Adina H; Simu I; Andone S; Bălaşa R
    CNS Neurol Disord Drug Targets; 2018; 17(10):780-792. PubMed ID: 30221605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
    Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
    JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Kostadinova II
    Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain].
    Piñol C
    Neurologia; 2016 May; 31(4):247-54. PubMed ID: 25976942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action.
    Balasa RI; Simu M; Voidazan S; Barcutean LI; Bajko Z; Hutanu A; Simu I; Maier S
    CNS Neurol Disord Drug Targets; 2017; 16(9):1018-1026. PubMed ID: 28782487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b.
    Ramirez-Ramirez V; Macias-Islas MA; Ortiz GG; Pacheco-Moises F; Torres-Sanchez ED; Sorto-Gomez TE; Cruz-Ramos JA; Orozco-Aviña G; Celis de la Rosa AJ
    Oxid Med Cell Longev; 2013; 2013():709493. PubMed ID: 23861993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
    Panitch H; Miller A; Paty D; Weinshenker B;
    Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
    Dhib-Jalbut S; Sumandeep S; Valenzuela R; Ito K; Patel P; Rametta M
    J Neuroimmunol; 2013 Jan; 254(1-2):131-40. PubMed ID: 22999187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.
    Touchette DR; Durgin TL; Wanke LA; Goodkin DE
    Clin Ther; 2003 Feb; 25(2):611-34. PubMed ID: 12749517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
    Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
    Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
    Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Betaferon efficiency indicators in the treatment of relapsing remitting form of multiple sclerosis.
    Suljic E; Sinanovic O; Kurtovic-Alajbegovic A; Klupka-Saric I
    Med Arch; 2013; 67(3):178-80. PubMed ID: 23848037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of interferon beta, cyclophosphamide and azathioprine on cytokine profile in patients with multiple sclerosis.
    Totaro R; Passacantando A; Russo T; Parzanese I; Rascente M; Marini C; Tonietti G; Carolei A
    Int J Immunopathol Pharmacol; 2005; 18(2):377-83. PubMed ID: 15888259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon beta-1b treatment in patients with relapsing--remitting multiple sclerosis under a standardized protocol in Spain.
    Arbizu T; Alvarez-Cermeño JC; Decap G; Fernández O; Uría DF; García Merino A; Izquierdo G; Montalbán X
    Acta Neurol Scand; 2000 Oct; 102(4):209-17. PubMed ID: 11071104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of clinical prognostic factors in Polish interferon beta-1b treated multiple sclerosis patients.
    Pietrzak A; Kalinowska-Łyszczarz A; Kozubski W; Michalak S
    Neurol Neurochir Pol; 2019; 53(6):458-465. PubMed ID: 31793659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon β-1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis.
    Lanzillo R; Di Somma C; Quarantelli M; Carotenuto A; Pivonello C; Moccia M; Cianflone A; Marsili A; Puorro G; Saccà F; Russo CV; De Luca Picione C; Ausiello F; Colao A; Brescia Morra V
    Eur J Neurol; 2017 Feb; 24(2):446-449. PubMed ID: 27982500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS.
    Gayo A; Mozo L; Suárez A; Tuñón A; Lahoz C; Gutiérrez C
    Neurology; 1999 Jun; 52(9):1764-70. PubMed ID: 10371521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.